Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANRO Alto Neuroscience	$3.13 -1.6%	$2.67	$1.60 ▼ $15.04	$84.74M	1.84	267,378 shs	77,872 shs
DBVT DBV Technologies	$9.91 +1.0%	$9.68	$2.20 ▼ $12.78	$271.44M	-0.58	209,828 shs	18,918 shs
FHTX Foghorn Therapeutics	$5.17 +6.2%	$5.15	$2.94 ▼ $10.25	$292.26M	3.05	130,967 shs	109,004 shs
LFCR Lifecore Biomedical	$7.74 +1.4%	$7.49	$3.68 ▼ $8.85	$289.55M	0.65	221,637 shs	179,239 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANRO Alto Neuroscience	+4.42%	+3.57%	+22.46%	+43.69%	-61.19%
DBVT DBV Technologies	+2.55%	+0.93%	-9.17%	-14.55%	+122.95%
FHTX Foghorn Therapeutics	+3.40%	-2.60%	-9.81%	+18.49%	-12.57%
LFCR Lifecore Biomedical	+5.68%	+5.24%	-8.07%	+14.39%	+40.52%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANRO Alto Neuroscience	2.0769 of 5 stars	3.3	1.0	1.7	0.0	1.3
DBVT DBV Technologies	3.545 of 5 stars	3.4	5.0	3.1	2.5	0.6
FHTX Foghorn Therapeutics	3.2918 of 5 stars	3.6	4.0	3.3	1.7	0.6
LFCR Lifecore Biomedical	0.6996 of 5 stars	1.3	0.0	1.7	4.2	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANRO Alto Neuroscience	2.57	Moderate Buy	$8.50	171.57% Upside
DBVT DBV Technologies	2.80	Moderate Buy	$14.75	48.84% Upside
FHTX Foghorn Therapeutics	3.14	Buy	$12.00	132.11% Upside
LFCR Lifecore Biomedical	2.50	Moderate Buy	$8.00	3.36% Upside

Current Analyst Ratings Breakdown

Latest ANRO, DBVT, LFCR, and FHTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/26/2025	ANRO Alto Neuroscience	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/26/2025	DBVT DBV Technologies	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/26/2025	DBVT DBV Technologies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$21.00
5/29/2025	DBVT DBV Technologies	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Sell	$7.25
5/27/2025	DBVT DBV Technologies	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
5/27/2025	DBVT DBV Technologies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$15.00 ➝ $21.00
5/21/2025	LFCR Lifecore Biomedical	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
5/15/2025	ANRO Alto Neuroscience	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$4.00 ➝ $4.00
5/15/2025	FHTX Foghorn Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$9.00 ➝ $9.00
5/14/2025	FHTX Foghorn Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 8/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANRO Alto Neuroscience	N/A	N/A	N/A	N/A	$5.62 per share	N/A
DBVT DBV Technologies	N/A	N/A	N/A	N/A	$3.15 per share	N/A
FHTX Foghorn Therapeutics	$22.60M	12.93	N/A	N/A	($1.36) per share	-3.80
LFCR Lifecore Biomedical	$128.87M	2.25	N/A	N/A	$0.37 per share	20.92

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANRO Alto Neuroscience	-$61.43M	-$2.34	N/A	N/A	N/A	N/A	-39.35%	-33.86%	N/A
DBVT DBV Technologies	-$113.92M	-$4.77	N/A	N/A	N/A	-3,220.49%	-287.15%	-138.83%	N/A
FHTX Foghorn Therapeutics	-$86.62M	-$1.19	N/A	N/A	N/A	-311.90%	N/A	-28.00%	N/A
LFCR Lifecore Biomedical	-$38.72M	-$1.31	N/A	N/A	N/A	-31.70%	-846.51%	-13.03%	10/3/2025 (Estimated)

Latest ANRO, DBVT, LFCR, and FHTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/25/2025	Q4 2025	LFCR Lifecore Biomedical	-$0.09	N/A	N/A	N/A	$35.36 million	N/A
8/14/2025	Q2 2025	FHTX Foghorn Therapeutics	-$0.32	N/A	N/A	N/A	N/A	N/A
8/12/2025	Q2 2025	ANRO Alto Neuroscience	-$0.57	-$0.65	-$0.08	-$0.65	N/A	N/A
8/7/2025	Q4 2025	LFCR Lifecore Biomedical	-$0.09	-$0.10	-$0.01	-$0.06	$35.36 million	$36.44 million
8/5/2025	Q2 2025	FHTX Foghorn Therapeutics	-$0.31	-$0.28	+$0.03	-$0.28	$7.62 million	$7.56 million
7/29/2025	Q2 2025	DBVT DBV Technologies	-$0.21	-$1.55	-$1.34	-$1.55	$0.64 million	$1.74 million
5/14/2025	Q1 2025	FHTX Foghorn Therapeutics	-$0.30	-$0.30	N/A	-$0.30	$4.96 million	$5.95 million
5/13/2025	Q1 2025	ANRO Alto Neuroscience	-$0.59	-$0.53	+$0.06	-$0.56	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANRO Alto Neuroscience	N/A	N/A	N/A	N/A	N/A
DBVT DBV Technologies	N/A	N/A	N/A	N/A	N/A
FHTX Foghorn Therapeutics	N/A	N/A	N/A	N/A	N/A
LFCR Lifecore Biomedical	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANRO Alto Neuroscience	0.15	22.53	22.53
DBVT DBV Technologies	N/A	2.45	2.45
FHTX Foghorn Therapeutics	N/A	2.62	2.62
LFCR Lifecore Biomedical	113.76	2.84	1.59

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANRO Alto Neuroscience	N/A
DBVT DBV Technologies	71.74%
FHTX Foghorn Therapeutics	61.55%
LFCR Lifecore Biomedical	83.36%

Insider Ownership

Company	Insider Ownership
ANRO Alto Neuroscience	N/A
DBVT DBV Technologies	1.44%
FHTX Foghorn Therapeutics	7.58%
LFCR Lifecore Biomedical	32.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANRO Alto Neuroscience	N/A	27.07 million	N/A	N/A
DBVT DBV Technologies	80	27.39 million	27.00 million	Optionable
FHTX Foghorn Therapeutics	120	56.53 million	52.25 million	Optionable
LFCR Lifecore Biomedical	690	37.41 million	25.36 million	Optionable

ANRO, DBVT, LFCR, and FHTX Headlines

Recent News About These Companies

Craig-Hallum Sticks to Its Buy Rating for Lifecore Biomedical (LFCR)

August 12 at 2:22 AM | theglobeandmail.com

Lifecore Biomedical Full Year 2025 Earnings: EPS Beats Expectations

August 11 at 8:21 PM | finance.yahoo.com

Lifecore Biomedical, Inc. (LFCR) Q4 2025 Earnings Call Transcript

August 8, 2025 | seekingalpha.com

Lifecore Biomedical Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update

August 7, 2025 | globenewswire.com

DCF Advisers LLC Sells 56,989 Shares of Lifecore Biomedical, Inc. (NASDAQ:LFCR)

August 4, 2025 | marketbeat.com

Lifecore Biomedical, Inc. to Report Q4 and Fiscal Year 2025 Financial Results on August 7, 2025

July 31, 2025 | quiverquant.comQ

Lifecore Biomedical to Report Fourth Quarter and Fiscal Year 2025 Financial Results on August 7, 2025

July 31, 2025 | globenewswire.com

Laughing Water Capital’s View on Lifecore Biomedical (LFCR)

July 24, 2025 | finance.yahoo.com

Laughing Water Capital’s View on Lifecore Biomedical Inc. (LFCR)

July 24, 2025 | insidermonkey.com

Lifecore Biomedical (NASDAQ:LFCR) Trading Down 2.5% - What's Next?

July 19, 2025 | marketbeat.com

Lifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 17, 2025 | globenewswire.com

Lifecore Biomedical Insider Ups Holding During Year

July 7, 2025 | finance.yahoo.com

Lifecore Signs 10-Year Manufacturing Deal To Support Novel Ophthalmic Therapy

June 18, 2025 | kalkinemedia.comK

Lifecore Biomedical: Inflecting Financials Over Next 3 Years

June 18, 2025 | seekingalpha.com

Lifecore Biomedical signs new 10-year commercial manufacturing and supply agreement

June 17, 2025 | msn.com

Bronstein, Gewirtz & Grossman, LLC Is Investigating Lifecore Biomedical, Inc. (LFCR) And Encourages Stockholders to Connect

June 17, 2025 | accessnewswire.comA

Lifecore Biomedical Signs New 10-Year Commercial Manufacturing and Supply Agreement with Key Existing Customer

June 17, 2025 | globenewswire.com

Lifecore Biomedical, Inc. (LFCR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

June 15, 2025 | accessnewswire.comA

Lifecore Receives Full Payment Early For $17 Mln Equipment Sale

June 14, 2025 | nasdaq.com

Lifecore Biomedical, Inc.: Lifecore Biomedical Receives Accelerated Payment of Remaining $10 Million in Proceeds from Prior Equipment Sale

June 12, 2025 | finanznachrichten.de

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Lifecore Biomedical, Inc. (LFCR) and Encourages Stockholders to Learn More About the Investigation

June 12, 2025 | accessnewswire.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANRO, DBVT, LFCR, and FHTX Company Descriptions

Alto Neuroscience NYSE:ANRO

$3.13 -0.05 (-1.57%)

Closing price 03:59 PM Eastern

Extended Trading

$3.10 -0.03 (-0.83%)

As of 06:35 PM Eastern

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient. The company was incorporated in 2019 and is headquartered in Los Altos, California.

DBV Technologies NASDAQ:DBVT

$9.91 +0.10 (+1.02%)

Closing price 03:58 PM Eastern

Extended Trading

$10.00 +0.09 (+0.90%)

As of 06:04 PM Eastern

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

Foghorn Therapeutics NASDAQ:FHTX

$5.17 +0.30 (+6.16%)

Closing price 04:00 PM Eastern

Extended Trading

$5.14 -0.03 (-0.48%)

As of 06:57 PM Eastern

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Lifecore Biomedical NASDAQ:LFCR

$7.74 +0.11 (+1.44%)

Closing price 04:00 PM Eastern

Extended Trading

$7.74 0.00 (0.00%)

As of 05:38 PM Eastern

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time